journal article·2020-06-23

Microfluidic Synthesis of Multimode Au@CoFeB-Rg3 Nanomedicines and Their Cytotoxicity and Anti-Tumor Effects

Weiwei Zhang, Xiaoxiong Zhao, Yuan Yuan, Fenglin Miao, Wengang Li, Shaoxia Ji, Xing Huang, Xinhua Chen, Tianan Jiang, David A. Weitz, Yujun Song

Chemistry of Materials· Volume 32· Issue 12
Publisher page

Abstract

Nanomedicines (i.e., Au@CoFeB-Rg3) were developed by conjugating multimode nanohybrids with active ingredients of natural herbs using Au@CoFeB nanoparticles as one model of multimode nanohybrids and the ginsenoside Rg3 as one model of active ingredients of natural herbs. Au@CoFeB nanoparticles were first synthesized using a temperature-programmed microfluidics process. Then, the surface of Au@CoFeB nanoparticles was modified via an amino-silane coupling agent of (3-aminopropyl) trimethoxysilane (APTMS) and then activated by the bifunctional amine-active cross-linker. They were thereafter conjugated to ginsenosides preactivated by APTMS by cross-linking the surface-activated nanohybrids, forming Au@CoFeB-Rg3 nanomedicines. Their multimode imaging functions were evaluated with the characterization of their magnetic and optical properties and the response to X-ray radiation. They can be optically detected via dark-field microscopy and can be imaged through X-ray computed tomography. They can also be used as magnetic resonance imaging contrast agents with excellent T2-weighted spin–echo imaging effects. Au@CoFeB-Rg3 nanomedicines exhibited distinct cytotoxicity and inhibitory effects on the proliferation of human hepatocellular carcinoma cells (HepG2/C3) and human chronic myeloid leukemia cells (K562) but were less toxic to 3T3 cells than other cells at concentrations more than 200 μg/mL. However, Au@CoFeB nanoparticles showed markedly lower cytotoxicity and inhibitory effects on the proliferation of these cell lines, particularly at concentrations <100 μg/mL, than Au@CoFeB-Rg3 nanomedicines. Clearly, there is a distinct synergistic effect between nanohybrids and Rg3. Additionally, Au@CoFeB nanohybrids showed almost no toxicity to Jurkat-CT cells at low concentrations (47 μg/mL), indicating that they may be used as multimode nanoprobes at a suitable concentration. These findings provide an efficient alternative for the synthesis of multifunctional antitumor nanomedicines based on multimode nanohybrids and active ingredients of natural resources.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Gold and Silver Nanoparticles Synthesis and Applications · Characterization and Applications of Magnetic Nanoparticles

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Center for Modern Physics Technology, School of Mathematics and Physics, University of Science and Technology Beijing, Beijing 100083, China

Zhengzhou Tianzhao Biotechnology Company, Ltd., 7 Dongqing Street, Zhengzhou High Tech Development Zone, Zhengzhou 451450, China

Physics Department, School of Engineering and Applied Science, Harvard University, Cambridge, Massachusetts 02138, United States

Department of Hepatobiliary Surgery, Xiang’an Hospital of Xiamen University, School of Medicine, Xiamen 361102, China

School of Materials Science and Engineering, Beihang University, Beijing 100091, China

Key Laboratory of Combined Multiorgan Transplantation, Ministry of Public Health, Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang 310003, China

Funding

National Natural Science Foundation of China · China Scholarship Council · development of a high sensitive magneto-optical biomolecular sen-sor experimental prototype · BRICS STI Framework Programmed by NSFC · ?1125? Zhihui Zhengzhou Talent project of Henan province · National S&T Major Project of China · ?100 talent plan? fund of Fujian province

References (100+)

Show source-provided references
1. Tekade, R.; Maheshwari, R.; Soni, N.; Tekade, M.; Chougule, M. Nanotechnology-Based Approaches for Targeting and Delivery of Drugs and Genes; Elsevier: Amsterdam, 2017; pp 3–61.10.1016/B978-0-12-809717-5.00001-4 ↗
2. 10.1208/s12249-014-0073-310.1208/s12249-014-0073-3 ↗
3. 10.1016/j.ijpharm.2017.05.03710.1016/j.ijpharm.2017.05.037 ↗
4. 10.4155/tde-2017-006210.4155/tde-2017-0062 ↗
5. 10.1016/j.jconrel.2018.11.01310.1016/j.jconrel.2018.11.013 ↗
6. 10.18632/oncotarget.2335910.18632/oncotarget.23359 ↗
7. 10.18632/oncotarget.2457210.18632/oncotarget.24572 ↗
8. 10.7150/thno.2513110.7150/thno.25131 ↗
9. Ushenko Y. A. · 2018 · 10728
10. 10.1080/21691401.2018.149966510.1080/21691401.2018.1499665 ↗
11. 10.1557/mrc.2018.4910.1557/mrc.2018.49 ↗
12. 10.1016/j.ejpb.2015.10.01510.1016/j.ejpb.2015.10.015 ↗
13. 10.1016/j.ejpb.2019.06.02510.1016/j.ejpb.2019.06.025 ↗
14. 10.1016/j.drudis.2019.05.00610.1016/j.drudis.2019.05.006 ↗
15. 10.1021/acs.bioconjchem.9b0045610.1021/acs.bioconjchem.9b00456 ↗
16. 10.2174/092986732666619071215402110.2174/0929867326666190712154021 ↗
17. 10.1016/B978-0-323-42862-0.00009-210.1016/B978-0-323-42862-0.00009-2 ↗
18. 10.1002/adhm.20170139910.1002/adhm.201701399 ↗
19. 10.1002/adhm.20180157610.1002/adhm.201801576 ↗
20. 10.2217/nnm-2016-040410.2217/nnm-2016-0404 ↗
21. Hock S. C. · Pda J. Pharmaceutical Sci. Technol. · 2011 · 65 · 177
22. 10.1158/1538-7445.AM2018-LB-07210.1158/1538-7445.AM2018-LB-072 ↗
23. 10.2174/138920022066619061415070810.2174/1389200220666190614150708 ↗
24. 10.1016/j.crhy.2011.06.00110.1016/j.crhy.2011.06.001 ↗
25. 10.1016/j.jsps.2015.03.00810.1016/j.jsps.2015.03.008 ↗
26. Azimi B. · Iranian Biomedical Journal · 2013 · 18 · 34
27. 10.1016/j.ijpharm.2013.07.03410.1016/j.ijpharm.2013.07.034 ↗
28. 10.1016/j.colsurfb.2009.09.00110.1016/j.colsurfb.2009.09.001 ↗
29. 10.1016/j.addr.2010.05.00610.1016/j.addr.2010.05.006 ↗
30. 10.1016/j.drudis.2014.11.01410.1016/j.drudis.2014.11.014 ↗
31. 10.1021/acs.chemrev.5b0010010.1021/acs.chemrev.5b00100 ↗
32. 10.1039/C4TC00988F10.1039/C4TC00988F ↗
33. 10.1021/cr900113j10.1021/cr900113j ↗
34. 10.2147/IJN.S6886110.2147/IJN.S68861 ↗
35. 10.1016/j.nano.2005.03.00210.1016/j.nano.2005.03.002 ↗
36. 10.1111/bjh.1558210.1111/bjh.15582 ↗
37. 10.1088/1361-6528/ab27ce10.1088/1361-6528/ab27ce ↗
38. 10.1021/acsami.8b0406010.1021/acsami.8b04060 ↗
39. 10.1186/s11671-019-3019-610.1186/s11671-019-3019-6 ↗
40. 10.1039/C5TC02279G10.1039/C5TC02279G ↗
41. 10.1080/20013078.2019.159760310.1080/20013078.2019.1597603 ↗
42. 10.1016/j.talanta.2019.05.11110.1016/j.talanta.2019.05.111 ↗
43. 10.1016/j.aca.2019.05.01310.1016/j.aca.2019.05.013 ↗
44. 10.1039/C7RA01224A10.1039/C7RA01224A ↗
45. 10.1039/C5RA17143A10.1039/C5RA17143A ↗
46. 10.1016/j.optcom.2018.12.03310.1016/j.optcom.2018.12.033 ↗
47. 10.1002/ejic.20110001710.1002/ejic.201100017 ↗
48. 10.1039/C6NR09122A10.1039/C6NR09122A ↗
49. 10.1002/jcp.2784910.1002/jcp.27849 ↗
50. 10.3390/polym1104074310.3390/polym11040743 ↗
51. Kim, S.; Jeong, S. H.; Song, J.; Lee, W. Fluorescent nanoparticles used in photoluminescent material for diagnosis or imaging of tumor, contains peptide moiety, spacer moiety for improving enzyme accessibility, and charge-bearing moiety including molecular sieve. Patent KR KR2019015685-A, 2019.
52. 10.4155/tde-2018-002010.4155/tde-2018-0020 ↗
53. 10.1038/srep4173210.1038/srep41732 ↗
54. 10.1002/smll.20160408410.1002/smll.201604084 ↗
55. 10.1007/s40820-018-0223-310.1007/s40820-018-0223-3 ↗
56. 10.1021/nl061942q10.1021/nl061942q ↗
57. 10.1021/nl015696o10.1021/nl015696o ↗
58. 10.1021/nl073015510.1021/nl0730155 ↗
59. 10.1021/acs.nanolett.7b0483810.1021/acs.nanolett.7b04838 ↗
60. 10.1021/acs.nanolett.9b0284110.1021/acs.nanolett.9b02841 ↗
61. 10.1021/acs.nanolett.7b0002610.1021/acs.nanolett.7b00026 ↗
62. 10.1039/C6RA17768A10.1039/C6RA17768A ↗
63. 10.1021/jp404402g10.1021/jp404402g ↗
64. 10.1021/acs.nanolett.6b0325110.1021/acs.nanolett.6b03251 ↗
65. 10.1002/slct.20190342710.1002/slct.201903427 ↗
66. 10.1016/j.biopha.2017.10.04310.1016/j.biopha.2017.10.043 ↗
67. 10.1158/1535-7163.MCT-12-005410.1158/1535-7163.MCT-12-0054 ↗
68. Shang Q. · Chinese Journal of Radiology · 2006 · 40 · 235
69. 10.3748/wjg.v17.i31.360510.3748/wjg.v17.i31.3605 ↗
70. 10.3390/molecules1604280210.3390/molecules16042802 ↗
71. Whitacre D. M. · 2013 · 225 · V10.1007/978-1-4614-6470-9 ↗
72. 10.1039/C3RA45382K10.1039/C3RA45382K ↗
73. 10.1006/jssc.2001.911710.1006/jssc.2001.9117 ↗
74. 10.1080/03639045.2018.144985310.1080/03639045.2018.1449853 ↗
75. 10.1007/s11671-006-9015-710.1007/s11671-006-9015-7 ↗
76. 10.1021/jp300118z10.1021/jp300118z ↗
77. 10.1039/B514191E10.1039/B514191E ↗
78. 10.1021/nl060083310.1021/nl0600833 ↗
79. 10.1002/adma.20070299410.1002/adma.200702994 ↗
80. 10.1021/cr068028210.1021/cr0680282 ↗
81. 10.1021/jp026731y10.1021/jp026731y ↗
82. 10.1134/1.185804310.1134/1.1858043 ↗
83. 10.1088/0022-3727/48/3/03550210.1088/0022-3727/48/3/035502 ↗
84. 10.1021/jp300118z10.1021/jp300118z ↗
85. 10.1016/j.matlet.2010.05.02510.1016/j.matlet.2010.05.025 ↗
86. 10.1021/jp404402g10.1021/jp404402g ↗
87. 10.1039/C5TC02279G10.1039/C5TC02279G ↗
88. 10.1021/la900986610.1021/la9009866 ↗
89. 10.1039/C4RA04168B10.1039/C4RA04168B ↗
90. 10.1103/PhysRevB.64.17442010.1103/PhysRevB.64.174420 ↗
91. 10.1016/j.jlumin.2019.11662710.1016/j.jlumin.2019.116627 ↗
92. 10.1016/j.matlet.2019.07.00510.1016/j.matlet.2019.07.005 ↗
93. 10.1016/j.apsusc.2010.03.10210.1016/j.apsusc.2010.03.102 ↗
94. 10.1039/C0NR00412J10.1039/C0NR00412J ↗
95. Xu, X. H. N.; Song, Y.; Nallathamby, P. Probing Membrane Transport of Single Live Cells Using Single-Molecule Detection and Single Nanoparticle Assay; John Wiley & Sons, Ltd, 2006; pp 41–70.10.1002/9780470119501.ch3 ↗
96. 10.1002/ejic.20110001710.1002/ejic.201100017 ↗
97. 10.1002/smll.20130326310.1002/smll.201303263 ↗
98. 10.1016/j.biomaterials.2017.11.01610.1016/j.biomaterials.2017.11.016 ↗
99. 10.1021/acsnano.5b0438010.1021/acsnano.5b04380 ↗
100. 10.1021/acsami.5b0435910.1021/acsami.5b04359 ↗